Appin. No.: 10/774,021

Amendment Dated October 17, 2006

Reply to Final Office Action of April 17, 2006

ARK-153US1

'Amendments to the Claims: This listing of claims will replace all prior versions, and listings, of claims in the application

Listing of Claims:

- 1. (Canceled)
- 2. (Canceled)
- 3. (Canceled)
- 4. (Canceled)
- 5. (Canceled)
- 6. (Canceled)
- 7. (Canceled)
- 8. (Canceled)
- 9. (Canceled)
- 10. (Canceled)
- 11. (Canceled)
- 12. (Canceled)
- 13. (Canceled)
- 14. (Canceled)
- 15. (Canceled)
- 16. (Canceled)
- 17. (Canceled)
- 18. (Canceled)
- 19. (Canceled)
- 20. (Canceled)
- 21. (Canceled)
- 22. (Canceled)
- 23. (Canceled)
- 24. (Canceled)
- 25. (Canceled)
- 26. (Canceled)
- 27. (Canceled)
- 28. (Canceled)
- 29. (Canceled)

Page 3 of 12

ME1\5900943.1

ARK-153US1

Appln. No.: 10/774,021

Amendment Dated October 17, 2006

Reply to Final Office Action of April 17, 2006

30. (Canceled)

- **3**1. (Canceled)
- 32. (Canceled)
- 33. (Canceled)
- 34. (Canceled)
- 35. (Canceled)
- (Canceled) 36.
- 37. (Canceled)
- (Canceled)

38.

41.

- (Canceled) 39.
- (Canceled) 40.
- 42. (Canceled)

(Canceled)

- (Canceled) 43.
- (Canceled) 44.
- 45. (canceled)
- A composition comprising glucosamine and an active egg 46. (Previously Presented) fraction, wherein the active egg fraction is purified from an egg obtained from an eggproducing animal that has been hyperimmunized with an immunogenic vaccine, said Immunogenic vaccine comprising antigens selected from the group consisting of bacterial, yiral, protozoan, fungal and cellular immunogens and mixtures thereof, and wherein said active egg fraction further comprises supranormal levels of an anti-inflammatory composition.
- (Previously Presented) The composition of claim 46 wherein the active egg fraction 47. comprises egg yolk.
- 48. (Cancelled)
- The composition of claim 46 wherein the glucosamine is (Previously Presented) 49. selected from the group consisting of glucosamine HCl and glucosamine sulfate.

Page 4 of 12

ME1\5900943.1

Appln. No.: 10/774,021
Amendment Dated October 17, 2006

Reply to Final Office Action of April 17, 2006

ARK-153US1

- 50. (Previously Presented) The composition of claim 46 wherein the amount of glucosamine comprises between approximately 10 milligrams and 5 grams.
- (Previously Presented) The composition of claim 46 wherein the Immunogenic vaccine comprises immunogens selected from the group consisting of: Escherichia coli, Escherichia coli (Aerobacter), Klebsiella pneumoniae, Pseudomonas aeruginosa, Salmonella typhimurium, Shigella dysenteriae, Salmonella enteriditis, Staphylococcus epidermidis, Staphylococcus simulans, Streptococcus pyogenes, type 1, Streptococcus pyogenes, type 3, Streptococcus pyogenes, type 5, Streptococcus pyogenes, type 8, Streptococcus pyogenes, type 12, Streptococcus pyogenes, type 14, Streptococcus pyogenes, type 18, Streptococcus pyogenes, type 22, Proteus vulgaris, Streptococcus agalactiae, Streptococcus mitis, Streptococcus mutans, Streptococcus salavarius, Streptococcus sanguls, Streptococcus pneumoniae, Propionibacterium acnes and Haemophilis influenzae
- 52. (Withdrawn) A method for reducing serum fibrinogen levels in a subject, the method comprising administering to the subject an effective amount of a composition comprising glucosamine and an active egg fraction wherein the active egg fraction is purified from an egg obtained from an egg-producing animal which has been hyperimmunized with an immunogenic vaccine, said immunogenic vaccine comprising antigens selected from the group consisting of bacterial, viral, protozoan, fungal and cellular immunogens and mixtures thereof.
- 53. (Withdrawn) The method of claim 52 wherein the effective amount of glucosamine comprises between approximately 10 milligrams and 5 grams.
- 54. (Withdrawn) The method of claim 52 wherein the composition is administered by a method selected from the group consisting of parenterally, subcutaneously, intravenously, intramuscularly, intraperltoneally, intranasally, orally and topically.
- 55. (Withdrawn) The method of claim 52 wherein the active egg fraction is dried to form a dried powder.

Page 5 of 12

ME1\5900943.1

Appln. No.: 10/774,021

Amendment Dated October 17, 2006

Reply to Final Office Action of April 17, 2006

ARK-153US1

- 56. (Withdrawn) A method for reducing or preventing the onset of rheumatoid arthritis in a subject, the method comprising administering to the subject an effective amount of a composition comprising glucosamine and an active egg fraction wherein the active egg fraction is purified from an egg an egg-producing animal which has been hyperimmunized with an immunogenic vaccine, said immunogenic vaccine comprising antigens selected from the group consisting of bacterial, viral, protozoan, fungal and cellular immunogens and mixtures thereof.
- 57. (Withdrawn) The method of claim 56 wherein the effective amount of glucosamine comprises between approximately 10 milligrams and 5 grams.
- 58. (Withdrawn) The method of claim 56 wherein the composition is administered by a method selected from the group consisting of parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, intranasally, orally and topically.
- 59. (Withdrawn) The method of claim 56 wherein the active egg fraction is dried to form a dried powder.